Increasing IL-18BP amount/activity (a therapeutic option already clinically validated to treat a rare systemic auto-inflammatory disease)44 could represent an interesting therapeutic perspective to treat MASLD/MASH as well as gut microbiota dysbiosis. The gene discussed is IL18BP; the disease is metabolic dysfunction-associated steatotic liver disease.